Phase II Dose Optimization with EZH2/EZH1 Inhibitor Tulmimetostat in Patients (pts) with Advanced Solid Tumors or Hematologic Malignancies.

Ana Oaknin,Kalyan Banda,Charles Drescher,Vincent Ribrag, Hedy L. Kindler,Harriet S. Walter,Alok Tewari,Elvire Pons-Tostivint,Nehal J. Lakhani,R. Donald Harvey,Ryan J. Sullivan,Pier Luigi Zinzani,Antonio Gonzalez Martin,Lauriane Eberst, Luis Manso Sanchez,Anjali Thakur, Lennart Kann, Archana Reddy,Nicola Faulhaber,Linda Duska

JOURNAL OF CLINICAL ONCOLOGY（2024）

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要